Supernus Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 6, 2024
July 23 2024 - 4:13PM
Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical
company focused on developing and commercializing products for the
treatment of central nervous system (CNS) diseases, today announced
that the Company expects to report financial and business results
for the second quarter of 2024 after the market closes on Tuesday,
August 6, 2024.
Jack Khattar, President and CEO, and Tim Dec,
Senior Vice President and CFO, will host a conference call to
present the second quarter 2024 financial and business results on
Tuesday, August 6, 2024 at 4:30 p.m. ET. Following management’s
prepared remarks and discussion of business results, the call will
be open for questions.
A live webcast will be accessible in the Events
& Presentations section of the Company’s Investor Relations
website at www.supernus.com/Investors.
Participants may also pre-register any time
before the call here. Once registration is completed, participants
will be provided a dial-in number with a personalized conference
code to access the call. Please dial in 15 minutes prior to the
start time.
Following the live call, a replay will be
available on the Company's Investor Relations website at
www.supernus.com/Investors. The webcast will be available on the
Company’s website for 60 days following the live call.
About Supernus Pharmaceuticals,
Inc.
Supernus Pharmaceuticals is a biopharmaceutical
company focused on developing and commercializing products for the
treatment of central nervous system (CNS) diseases.
Our diverse neuroscience portfolio includes
approved treatments for epilepsy, migraine, ADHD, hypomobility in
Parkinson’s disease (PD), cervical dystonia, chronic sialorrhea,
dyskinesia in PD patients receiving levodopa-based therapy, and
drug-induced extrapyramidal reactions in adult patients. We are
developing a broad range of novel CNS product candidates including
new potential treatments for hypomobility in PD, epilepsy,
depression, and other CNS disorders.
For more information, please visit
www.supernus.com.
CONTACTS:
Jack A. Khattar, President and CEO Timothy C.
Dec, Senior Vice President and CFOSupernus Pharmaceuticals,
Inc.Tel: (301) 838-2591
or
INVESTOR CONTACT:Peter VozzoICR WestwickeOffice:
(443) 213-0505Mobile: (443) 377-4767Email:
peter.vozzo@westwicke.com
Supernus Pharmaceuticals (NASDAQ:SUPN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Supernus Pharmaceuticals (NASDAQ:SUPN)
Historical Stock Chart
From Jul 2023 to Jul 2024